Development and characterization of ADC999: A novel, potent orally available Wee1 inhibitor with robust antitumor efficacy in vivo

被引：0
|
作者：
Gavory, Gerald
O'Dowd, Colin
Rozycka, Ewelina
Boyd, Caroline
Gorges, Beronia
McLean, Estelle
Daubriac, Julien
Rountree, Shane
Shepherd, Steven
Burton, Stephanie
McFarland, Mary
Treder, Adam
Wilkinson, Andy
Burkamp, Frank
Harrison, Tim
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-LB-319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-319
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models
    Ardini, Elena
    Menichincheri, Maria
    De Ponti, Cristina
    Amboldi, Nadia
    Ballinari, Dario
    Saccardo, Maria Beatrice
    Croci, Valter
    Stellari, Fabio
    Texido, Gemma
    Orsini, Paolo
    Perrone, Ettore
    Bandiera, Tiziano
    Borgia, Andrea Lombardi
    Lansen, Jaqueline
    Isacchi, Antonella
    Colotta, Francesco
    Pesenti, Enrico
    Magnaghi, Paola
    Galvani, Arturo
    [J]. CANCER RESEARCH, 2009, 69
  • [22] U3-1402a, a novel HER3-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent antitumor efficacy
    Ueno, Suguru
    Hirotani, Kenji
    Abraham, Reimar
    Blum, Sabine
    Frankenberger, Birgit
    Redondo-Muller, Mauricio
    Bange, Johannes
    Ogitani, Yusuke
    Zembutsu, Akiko
    Morita, Koji
    Nakada, Takashi
    Majima, Shuji
    Abe, Yuki
    Agatsuma, Toshinori
    [J]. CANCER RESEARCH, 2017, 77
  • [23] MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil
    Hirai, Hiroshi
    Arai, Tsuyoshi
    Okada, Megumu
    Nishibata, Toshihide
    Kobayashi, Makiko
    Sakai, Naoko
    Imagaki, Kazuhide
    Ohtani, Junko
    Sakai, Takumi
    Yoshizumi, Takashi
    Mizuarai, Shinji
    Iwasawa, Yoshikazu
    Kotani, Hidehito
    [J]. CANCER BIOLOGY & THERAPY, 2010, 9 (07) : 514 - 522
  • [24] NVP-AUY922:: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy
    Jensen, Michael Rugaard
    Schoepfer, Joseph
    Radimersky, Thomas
    Massey, Andrew
    Brueggen, Josef
    Schweitzer, Alain
    Pfaar, Ulrike
    Ruetz, Stephan
    Guy, Chantal
    Buckler, Alan
    Schnell, Christian
    Cozens, Robert
    Brough, Paul
    Drysdale, Martin
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Chene, Patrick
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
  • [25] NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer
    Montagnoli, Alessia
    Menichincheri, Maria
    Amboldi, Nadia
    Ballinari, Dario
    Ciomei, Marina
    Fiorentini, Francesco
    Lupi, Rosita
    Pezzetta, Daniele
    Rainoldi, Sonia
    Pezzetta, Daniele
    Felder, Eduard
    Isacchi, Antonella
    Pesenti, Enrico
    Galvani, Arturo
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [26] Preclinical characterization of ARRY-575: a potent, selective, and orally bio-available small molecule inhibitor of Chk1
    Humphries, M. J.
    von Carlowitz, I.
    Le Huerou, Y. L.
    Randolph, N.
    Gunawardana, I.
    Mohr, P. J.
    Wang, B.
    Lyon, M. A.
    Chicarelli, M.
    Sullivan, F.
    Blake, J. F.
    Winski, S. L.
    Wallace, E.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 23 - 23
  • [27] YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
    Xia, Yong
    Song, Xuejiao
    Li, Deliang
    Ye, Tinghong
    Xu, Youzhi
    Lin, Hongjun
    Meng, Nana
    Li, Guobo
    Deng, Senyi
    Zhang, Shuang
    Liu, Li
    Zhu, Yongxia
    Zeng, Jun
    Lei, Qian
    Pan, Youli
    Wei, Yuquan
    Zhao, Yinglan
    Yu, Luoting
    [J]. SCIENTIFIC REPORTS, 2014, 4
  • [28] YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
    Yong Xia
    Xuejiao Song
    Deliang Li
    Tinghong Ye
    Youzhi Xu
    Hongjun Lin
    Nana Meng
    Guobo Li
    Senyi Deng
    Shuang Zhang
    Li Liu
    Yongxia Zhu
    Jun Zeng
    Qian Lei
    Youli Pan
    Yuquan Wei
    Yinglan Zhao
    Luoting Yu
    [J]. Scientific Reports, 4
  • [29] Preclinical In Vivo Characterization of UCB0599, an Orally Available, Small Molecule Inhibitor of α-Synuclein Misfolding in Development for Parskinson's Disease
    Price, Diana
    Khan, Asma
    Angers, Rachel
    Cardenas, Alvaro
    Prato, Maria Key
    Citron, Martin
    Bonhaus, Doug
    Biere, Anja-Leona
    [J]. NEUROLOGY, 2022, 98 (18)
  • [30] Preclinical in vitro and in vivo evaluation of antitumor activity of UD-017, a novel selective and orally available CDK7 inhibitor, in colorectal cancer.
    Ogi, Sayaka
    Aga, Yasuhiro
    Onuma, Kazuhiro
    Sunamoto, Hidetoshi
    Matsushita, Takashi
    Ogawa, Ayumi
    Hasegawa, Tohru
    Kono, Shigeyuki
    Iwase, Noriaki
    Tokunaga, Yasunori
    Ushiyama, Shigeru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345